Post-translational modification of MALT1 and its role in B cell- and T cell-related diseases

• Published in: Biochemical pharmacology Vol. 198; p. 114977
• Main Authors: Zhang, Yi-Yue, Peng, Jun, Luo, Xiu-Ju
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.04.2022
• Subjects: Apoptosis Regulatory Proteins - metabolism; B-Cell CLL-Lymphoma 10 Protein - genetics; B-Cell CLL-Lymphoma 10 Protein - metabolism; BCR; CARD Signaling Adaptor Proteins; Caspases - genetics; Caspases - metabolism; Guanylate Cyclase - genetics; Guanylate Cyclase - metabolism; MALT1; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein - genetics; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein - metabolism; NF-kappa B - metabolism; Phosphorylation; Protein Processing, Post-Translational; T-Lymphocytes - metabolism; TCR; Ubiquitin; Ubiquitin; TCR; Phosphorylation; JNK; cIAP2; IBD; TNF; MALT1; RelB; BAFF-R; MAGUK; TAK1; HECTD3; Bcl10; HOIL1; PKC; LUBAC; BCR; CYLD; NIK; USP2a; TRAF6; Regnase-1; NK; mTORC1; CARD11; Ig; DC; A20
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2022.114977

[Display omitted] Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a multifunctional protein. MALT1 functions as an adaptor protein to assemble and recruit proteins such as B-cell lymphoma 10 (BCL10) and caspase-recruitment domain (CARD)-containing coiled-coil protein 11 (CARD11). Conversely it also acts as a paracaspase to cleave specified substrates. Because of its involvement in immunity, inflammation and cancer through its dual functions of scaffolding and catalytic activity, MALT1 is becoming a promising therapeutic target in B cell- and T cell-related diseases. There is growing evidence that the function of MALT1 is subtly modulated via post-translational modifications. This review summarized recent progress in relevant studies regarding the physiological and pathophysiological functions of MALT1, post-translational modifications of MALT1 and its role in B cell- and T cell- related diseases. In addition, the current available MALT1 inhibitors were also discussed.